PD-1 as a potential target in cancer therapy

por McDermott, David F, Atkins, Michael B
Publicado 2013

Management of metastatic renal cell carcinoma in patients with poor prognosis

por Bullock, Andrea, McDermott, David F, Atkins, Michael B
Publicado 2010

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

por Gao, Xin, McDermott, David F., Michaelson, M. Dror
Publicado 2019

LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma

por McDermott, David F, Peer, Avivit, Agarwal, Neeraj, Atkins, Michael B, Cornell, Jerry, Perini, Rodolfo F, Grossmann, Kenneth F, Gurney, Howard
Publicado 2023

FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

por Chen, James L, Appelbaum, Daniel E, Kocherginsky, Masha, Cowey, Charles L, Kimryn Rathmell, Wendy, McDermott, David F, Stadler, Walter M
Publicado 2013

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates

por Wong, Michael K, Daniels, Gregory A, Kaufman, Howard L, McDermott, David F, Morse, Michael A, Aung, Sandra, Lowder, James N
Publicado 2013

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

por Wong, Michael K, Kaufman, Howard L, Daniels, Gregory A, McDermott, David F, Aung, Sandra, Lowder, James N, Morse, Michael A
Publicado 2014

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)

por Kaufman, Howard L., Wong, Michael K., Daniels, Gregory A., McDermott, David F., Aung, Sandra, Lowder, James N., Morse, Michael A.
Publicado 2014

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

por Mantia, Charlene M., Werner, Lillian, Stwalley, Brian, Ritchings, Corey, Tarhini, Ahmad A., Atkins, Michael B., McDermott, David F., Regan, Meredith M.
Publicado 2021

Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review

por Schoenfeld, Jonathan D., Mahadevan, Anand, Floyd, Scott R., Dyer, Michael A., Catalano, Paul J., Alexander, Brian M., McDermott, David F., Kaplan, Irving D.
Publicado 2015

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3

por Meza, Luis, McDermott, David F, Escudier, Bernard, Hutson, Thomas E, Porta, Camillo, Verzoni, Elena, Atkins, Michael B, Kasturi, Vijay, Pal, Sumanta K, Rini, Brian
Publicado 2022

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma

por Atkins, Michael B, Gupta, Shilpa, Choueiri, Toni K, McDermott, David F, Puzanov, Igor, Tarazi, Jamal, Keefe, Stephen, Rosbrook, Brad, Chakrabarti, Debasis, Plimack, Elizabeth R
Publicado 2015

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use...

por Wong, Michael KK, Morse, Michael A, McDermott, David F, Clark, Joseph I, Kaufman, Howard L, Daniels, Gregory A, Perritt, Jessica C, Hua, Hong, Aung, Sandra
Publicado 2015

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)

por Clark, Joseph I, Morse, Michael A, Wong, Michael KK, McDermott, David F, Kaufman, Howard L, Daniels, Gregory A, Perritt, Jessica C, Hua, Hong, Aung, Sandra
Publicado 2015

Regulation of HHLA2 expression in kidney cancer and myeloid cells

por Shigemura, Tomonari, Perrot, Nahuel, Huang, Zimo, Bhatt, Rupal S., Sheshdeh, Aseman Bagheri, Ahmar, Nourhan El, Ghandour, Fatme, Signoretti, Sabina, McDermott, David F., Freeman, Gordon J., Mahoney, Kathleen M.
Publicado 2023

Soluble PD-L1 as an early marker of progressive disease on nivolumab

por Mahoney, Kathleen M, Ross-Macdonald, Petra, Yuan, Long, Song, Linan, Veras, Eliseo, Wind-Rotolo, Megan, McDermott, David F, Stephen Hodi, F, Choueiri, Toni K, Freeman, Gordon J
Publicado 2022

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma

por Chandar, Ashwin, Silk, Ann W, Clark, Joseph I, Daniels, Gregory A, McDermott, David F, Morse, Michael, Wong, Michael KK, Stein, Mark, Mehnert, Janice, Danish, Shabbar, Aung, Sandra, Kaufman, Howard L
Publicado 2015

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

por Hamieh, Lana, Choueiri, Toni K., Ogórek, Barbara, Khabibullin, Damir, Rosebrock, Daniel, Livitz, Dimitri, Fay, Andre, Pignon, Jean-Christophe, McDermott, David F., Agarwal, Neeraj, Gao, Wenhua, Signoretti, Sabina, Kwiatkowski, David J.
Publicado 2018

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma

por Silk, Ann W., Curti, Brendan, Bryan, Jennifer, Saunders, Tracie, Shih, Weichung, Kane, Michael P., Hannon, Phoebe, Fountain, Christopher, Felcher, Jessica, Zloza, Andrew, Kaufman, Howard L., Mehnert, Janice M., McDermott, David F.
Publicado 2023

Circulating KIM-1 is a minimally invasive biomarker correlated with treatment response to nivolumab in patients with metastatic renal cell carcinoma

por Xu, Wenxin, Vemula, Sai V, Niman, Samuel M, Liu, Xiaowen, Takakura, Ayumi, Huang, Zimo, Choueiri, Toni K, Freedman, Matthew L, Catalano, Paul J, Bonventre, Joseph V, Gupta, Saurabh, McDermott, David F, Bhatt, Rupal S
Publicado 2023